TCGA-77-8133-01A-12R-2247-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.480
- E2F_TARGETS+0.440
- MITOTIC_SPINDLE+0.390
- WNT_BETA_CATENIN_SIGNALING+0.390
- PI3K_AKT_MTOR_SIGNALING+0.290
- APICAL_SURFACE+0.210
- APICAL_JUNCTION+0.120
- HEDGEHOG_SIGNALING+0.100
- P53_PATHWAY+0.100
- ALLOGRAFT_REJECTION+0.090
Top 10 suppressed
- ANGIOGENESIS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- COAGULATION-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- GLYCOLYSIS-0.350
- INTERFERON_GAMMA_RESPONSE-0.280
- TNFA_SIGNALING_VIA_NFKB-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- XENOBIOTIC_METABOLISM-0.260
- ADIPOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932832 | — | — | 0.755 |
| 2 | SRR8613784 | — | E | 0.751 |
| 3 | BS_N5DVEJXT | EPN | Supratentorial EPN | 0.749 |
| 4 | 766e896b-b5a2-49ee-be4c-e95670a16fdc | — | — | 0.749 |
| 5 | SRR8613731 | — | E | 0.745 |
| 6 | SRR8613730 | — | D | 0.745 |
| 7 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.743 |
| 8 | SRR8752373 | — | — | 0.739 |
| 9 | sclc232230_S83.txt | — | cohortSC | 0.733 |
| 10 | SRR1480875 | GTEX | — | 0.732 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |